{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:47:06Z","timestamp":1788565626401,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017569","name":"Salzburger Landesregierung","doi-asserted-by":"publisher","award":["20102\/F2300645-FPR"],"award-info":[{"award-number":["20102\/F2300645-FPR"]}],"id":[{"id":"10.13039\/501100017569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017569","name":"Salzburger Landesregierung","doi-asserted-by":"publisher","award":["20204-WISS\/263\/6-6022"],"award-info":[{"award-number":["20204-WISS\/263\/6-6022"]}],"id":[{"id":"10.13039\/501100017569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017569","name":"Salzburger Landesregierung","doi-asserted-by":"publisher","award":["20204-WISS\/225\/197-2019"],"award-info":[{"award-number":["20204-WISS\/225\/197-2019"]}],"id":[{"id":"10.13039\/501100017569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017569","name":"Salzburger Landesregierung","doi-asserted-by":"publisher","award":["20102-F1901166-KZP"],"award-info":[{"award-number":["20102-F1901166-KZP"]}],"id":[{"id":"10.13039\/501100017569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Clinical research on innovative therapies for the rare genodermatosis epidermolysis bullosa (EB) faces significant challenges, including small sample sizes, disease heterogeneity with intra- and inter-individual variability, limited understanding of pathogenic mechanisms and natural disease course, as well as the lack of patient-centred core outcomes. Moreover, existing tools and techniques to assess disease activity and dynamics are heterogeneous, inconsistent, and may fail to consider or inaccurately emphasize particularities of individual patients and distinct EB subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In order to exemplify the differences between keratin-associated subtypes of EB simplex (k-EBS), we summarized respective clinical characteristics in a narrative way. In addition, we performed a systematic review of the literature published over the last 5 years, with the aim to give an overview on outcomes and their assessments used in these patient populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This review summarises the methodological scope, strengths and limitations of outcome assessments in clinical trials for the k-EBS, a group of inherited skin fragility diseases characterised by their distinct phenotype of epidermal blistering.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By presenting an overview of the clinical spectrum of k-EBS, we identified key gaps in current assessment methodologies and propose alternative approaches to optimise the evaluation of skin blistering, with the aim of enhancing the accuracy, reliability, and patient-relevance of clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03822-0","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:59:21Z","timestamp":1750395561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Keratin-associated epidermolysis bullosa simplex: phenotypes and challenges in clinical trials \u2013 a narrative review and systematic update"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-3890","authenticated-orcid":false,"given":"Verena","family":"Wally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Welponer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Wiesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Diem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Geroldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia I.","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Dorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina Pi\u00f1\u00f3n","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann W.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Laimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"3822_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis Bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183:614\u201327.","journal-title":"Br J Dermatol"},{"key":"3822_CR2","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI38177","volume":"119","author":"PA Coulombe","year":"2009","unstructured":"Coulombe PA, Kerns ML, Fuchs E. Epidermolysis Bullosa simplex: a paradigm for disorders of tissue fragility. J Clin Invest. 2009;119:1784\u201393.","journal-title":"J Clin Invest"},{"key":"3822_CR3","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","volume":"387","author":"SV Guide","year":"2022","unstructured":"Guide SV, Gonzalez ME, Bagci IS, Agostini B, Chen H, Feeney G, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis Bullosa. N Engl J Med. 2022;387:2211\u20139.","journal-title":"N Engl J Med"},{"key":"3822_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/bjd\/ljac001","volume":"188","author":"JS Kern","year":"2023","unstructured":"Kern JS, Sprecher E, Fernandez MF, Schauer F, Bodemer C, Cunningham T, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis Bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol. 2023;188:12\u201321.","journal-title":"Br J Dermatol"},{"key":"3822_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13023-022-02433-3","volume":"17","author":"JY So","year":"2022","unstructured":"So JY, Fulchand S, Wong CY, Li S, Nazaroff J, Gorell ES, et al. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis Bullosa simplex. Orphanet J Rare Dis. 2022;17:270.","journal-title":"Orphanet J Rare Dis"},{"key":"3822_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1046\/j.1365-2133.2000.03358.x","volume":"142","author":"HM Horn","year":"2000","unstructured":"Horn HM, Tidman MJ. The clinical spectrum of epidermolysis Bullosa simplex. Br J Dermatol. 2000;142:468\u201372.","journal-title":"Br J Dermatol"},{"key":"3822_CR7","doi-asserted-by":"crossref","unstructured":"Bchetnia M, Powell J, McCuaig C, Boucher-Lafleur AM, Morin C, Dupere A, Laprise C. Pathological mechanisms involved in epidermolysis Bullosa simplex: current knowledge and therapeutic perspectives. Int J Mol Sci 2024; 25.","DOI":"10.3390\/ijms25179495"},{"key":"3822_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","volume":"152","author":"JD Fine","year":"2016","unstructured":"Fine JD. Epidemiology of inherited epidermolysis Bullosa based on incidence and prevalence estimates from the National epidermolysis Bullosa registry. JAMA Dermatol. 2016;152:1231\u20138.","journal-title":"JAMA Dermatol"},{"key":"3822_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjd.20958","volume":"186","author":"G Petrof","year":"2022","unstructured":"Petrof G, Papanikolaou M, Martinez AE, Mellerio JE, McGrath JA, Bardhan A, et al. The epidemiology of epidermolysis Bullosa in England and Wales: data from the National epidermolysis Bullosa database. Br J Dermatol. 2022;186:843\u20138.","journal-title":"Br J Dermatol"},{"key":"3822_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13023-017-0666-5","volume":"12","author":"J Brun","year":"2017","unstructured":"Brun J, Chiaverini C, Devos C, Leclerc-Mercier S, Mazereeuw J, Bourrat E, et al. Pain and quality of life evaluation in patients with localized epidermolysis Bullosa simplex. Orphanet J Rare Dis. 2017;12:119.","journal-title":"Orphanet J Rare Dis"},{"key":"3822_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","volume":"70","author":"JD Fine","year":"2014","unstructured":"Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, et al. Inherited epidermolysis Bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70:1103\u201326.","journal-title":"J Am Acad Dermatol"},{"key":"3822_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1365-2133.2011.10428.x","volume":"165","author":"M Garcia","year":"2011","unstructured":"Garcia M, Santiago JL, Terron A, Hernandez-Martin A, Vicente A, Fortuny C, et al. Two novel recessive mutations in KRT14 identified in a cohort of 21 Spanish families with epidermolysis Bullosa simplex. Br J Dermatol. 2011;165:683\u201392.","journal-title":"Br J Dermatol"},{"key":"3822_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/ced\/llac129","volume":"48","author":"L Banner","year":"2023","unstructured":"Banner L, Cohen A, McGrath L, Nikbakht N, South AP. A novel KRT14 null mutation leads to autosomal recessive epidermolysis Bullosa simplex. Clin Exp Dermatol. 2023;48:431\u20133.","journal-title":"Clin Exp Dermatol"},{"key":"3822_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1046\/j.1365-2230.2003.01218.x","volume":"28","author":"CM Lanschuetzer","year":"2003","unstructured":"Lanschuetzer CM, Klausegger A, Pohla-Gubo G, Hametner R, Richard G, Uitto J, et al. A novel homozygous nonsense deletion\/insertion mutation in the keratin 14 gene (Y248X; 744delC\/insAG) causes recessive epidermolysis Bullosa simplex type Kobner. Clin Exp Dermatol. 2003;28:77\u20139.","journal-title":"Clin Exp Dermatol"},{"key":"3822_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/ng0493-327","volume":"3","author":"A Hovnanian","year":"1993","unstructured":"Hovnanian A, Pollack E, Hilal L, Rochat A, Prost C, Barrandon Y, Goossens M. A missense mutation in the rod domain of keratin 14 associated with recessive epidermolysis Bullosa simplex. Nat Genet. 1993;3:327\u201332.","journal-title":"Nat Genet"},{"key":"3822_CR16","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1038\/jid.2011.166","volume":"131","author":"M Titeux","year":"2011","unstructured":"Titeux M, Decha A, Pironon N, Tonasso L, Gasc G, Mejia JE, et al. A new case of keratin 14 functional knockout causes severe recessive EBS and questions the haploinsufficiency model of Naegeli-Franceschetti-Jadassohn syndrome. J Invest Dermatol. 2011;131:2131\u20133.","journal-title":"J Invest Dermatol"},{"key":"3822_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/sj.jid.5700154","volume":"126","author":"M Titeux","year":"2006","unstructured":"Titeux M, Mazereeuw-Hautier J, Hadj-Rabia S, Prost C, Tonasso L, Fraitag S, et al. Three severe cases of EBS Dowling-Meara caused by missense and frameshift mutations in the keratin 14 gene. J Invest Dermatol. 2006;126:773\u20136.","journal-title":"J Invest Dermatol"},{"key":"3822_CR18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/bjd.15053","volume":"177","author":"E Kim","year":"2017","unstructured":"Kim E, Harris A, Hyland V, Murrell DF. Digenic inheritance in epidermolysis Bullosa simplex involving two novel mutations in KRT5 and KRT14. Br J Dermatol. 2017;177:262\u20134.","journal-title":"Br J Dermatol"},{"key":"3822_CR19","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1038\/jid.2012.229","volume":"132","author":"G Padalon-Brauch","year":"2012","unstructured":"Padalon-Brauch G, Ben Amitai D, Vodo D, Harel A, Sarig O, Sprecher E, Mashiah J. Digenic inheritance in epidermolysis Bullosa simplex. J Invest Dermatol. 2012;132:2852\u20134.","journal-title":"J Invest Dermatol"},{"key":"3822_CR20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/bjd.12624","volume":"170","author":"K Wertheim-Tysarowska","year":"2014","unstructured":"Wertheim-Tysarowska K, Sota J, Kutkowska-Kazmierczak A, Wozniak K, Bal J, Kowalewski C. Coexistence of KRT14 and KRT5 mutations in a Polish patient with epidermolysis Bullosa simplex. Br J Dermatol. 2014;170:468\u20139.","journal-title":"Br J Dermatol"},{"key":"3822_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdermsci.2023.03.002","volume":"110","author":"Z Gong","year":"2023","unstructured":"Gong Z, Zou X, Xue R, Zhu X, Jiang X. Large intragenic deletion of KRT14 causes autosomal-dominant epidermolysis Bullosa simplex with generalized hyperpigmentation. J Dermatol Sci. 2023;110:27\u201330.","journal-title":"J Dermatol Sci"},{"key":"3822_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bjd.16897","volume":"180","author":"E Castela","year":"2019","unstructured":"Castela E, Tulic MK, Rozieres A, Bourrat E, Nicolas JF, Kanitakis J, et al. Epidermolysis Bullosa simplex generalized severe induces a T helper 17 response and is improved by Apremilast treatment. Br J Dermatol. 2019;180:357\u201364.","journal-title":"Br J Dermatol"},{"key":"3822_CR23","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/jid.2013.31","volume":"133","author":"V Wally","year":"2013","unstructured":"Wally V, Lettner T, Peking P, Peckl-Schmid D, Murauer EM, Hainzl S, et al. The pathogenetic role of IL-1beta in severe epidermolysis Bullosa simplex. J Invest Dermatol. 2013;133:1901\u20133.","journal-title":"J Invest Dermatol"},{"key":"3822_CR24","doi-asserted-by":"crossref","unstructured":"Evtushenko NA, Beilin AK, Kosykh AV, Vorotelyak EA, Gurskaya NG. Keratins as an inflammation trigger point in epidermolysis Bullosa simplex. Int J Mol Sci 2021; 22.","DOI":"10.3390\/ijms222212446"},{"key":"3822_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1525-1470.2012.01748.x","volume":"30","author":"B Echeverria-Garcia","year":"2013","unstructured":"Echeverria-Garcia B, Vicente A, Hernandez A, Mascaro JM, Colmenero I, Terron A, et al. Epidermolysis Bullosa simplex with mottled pigmentation: a family report and review. Pediatr Dermatol. 2013;30:125\u201331.","journal-title":"Pediatr Dermatol"},{"key":"3822_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/pde.14087","volume":"37","author":"B Yalici-Armagan","year":"2020","unstructured":"Yalici-Armagan B, Kabacam S, Taskiran ZE, Gokoz O, Utine GE, Ersoy-Evans S. A novel mutation of keratin 5 in epidermolysis Bullosa simplex with migratory circinate erythema. Pediatr Dermatol. 2020;37:358\u201361.","journal-title":"Pediatr Dermatol"},{"key":"3822_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1750-1172-9-76","volume":"9","author":"M El Hachem","year":"2014","unstructured":"El Hachem M, Zambruno G, Bourdon-Lanoy E, Ciasulli A, Buisson C, Hadj-Rabia S, et al. Multicentre consensus recommendations for skin care in inherited epidermolysis Bullosa. Orphanet J Rare Dis. 2014;9:76.","journal-title":"Orphanet J Rare Dis"},{"key":"3822_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine JD, Harper N, Has C, et al. Epidermolysis Bullosa. Nat Rev Dis Primers. 2020;6:78.","journal-title":"Nat Rev Dis Primers"},{"key":"3822_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/bjd\/ljad077","volume":"189","author":"EWH Korte","year":"2023","unstructured":"Korte EWH, Welponer T, Kottner J, van der Werf S, van den Akker PC, Horvath B, et al. Heterogeneity of reported outcomes in epidermolysis Bullosa clinical research: a scoping review as a first step towards outcome harmonization. Br J Dermatol. 2023;189:80\u201390.","journal-title":"Br J Dermatol"},{"key":"3822_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jdcr.2021.03.025","volume":"12","author":"NM AlKhawajah","year":"2021","unstructured":"AlKhawajah NM, AlKhawajah MM, Aljomah NA, Alabduljabbar AA, Alkeraye S. Epidermolysis Bullosa simplex clearance after nasopharyngeal carcinoma treatment. JAAD Case Rep. 2021;12:60\u20133.","journal-title":"JAAD Case Rep"},{"key":"3822_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jid.2021.07.170","volume":"142","author":"GH Lee","year":"2022","unstructured":"Lee GH, Lekwuttikarn R, Tafoya E, Martin M, Sarin KY, Teng JM. Transcriptomic repositioning analysis identifies mTOR inhibitor as potential therapy for epidermolysis Bullosa simplex. J Invest Dermatol. 2022;142:382\u20139.","journal-title":"J Invest Dermatol"},{"key":"3822_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/1346-8138.17037","volume":"51","author":"X Sun","year":"2024","unstructured":"Sun X, Zhang J, Yang Q, Lin J. Treatment of epidermolysis Bullosa simplex with dupilumab. J Dermatol. 2024;51:131\u20132.","journal-title":"J Dermatol"},{"key":"3822_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/ijd.16605","volume":"62","author":"M Melendez","year":"2023","unstructured":"Melendez M, Osborn L, Bowers E. Low-dose botulinum toxin improves disease activity and quality of life in epidermolysis Bullosa simplex. Int J Dermatol. 2023;62:466\u20138.","journal-title":"Int J Dermatol"},{"key":"3822_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/jdv.19646","volume":"38","author":"B Koszegi","year":"2024","unstructured":"Koszegi B, Murrell DF. Dapsone for the management of severe epidermolysis Bullosa simplex: A case report and evidence for a repurposing trial. J Eur Acad Dermatol Venereol. 2024;38:420\u20131.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3822_CR35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13023-020-01467-9","volume":"15","author":"V Wally","year":"2020","unstructured":"Wally V, Reisenberger M, Kitzmuller S, Laimer M. Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis Bullosa. Orphanet J Rare Dis. 2020;15:292.","journal-title":"Orphanet J Rare Dis"},{"key":"3822_CR36","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jaad.2018.01.019","volume":"78","author":"V Wally","year":"2018","unstructured":"Wally V, Hovnanian A, Ly J, Buckova H, Brunner V, Lettner T, et al. Diacerein orphan drug development for epidermolysis Bullosa simplex: A phase 2\/3 randomized, placebo-controlled, double-blind clinical trial. J Am Acad Dermatol. 2018;78:892\u2013901.","journal-title":"J Am Acad Dermatol"},{"key":"3822_CR37","doi-asserted-by":"publisher","first-page":"S196","DOI":"10.1016\/j.jid.2017.07.120","volume":"137","author":"JW Bauer","year":"2017","unstructured":"Bauer JW, Bruckner A, Browning J, Hovnanian A. Development and validation of an investigators global assessment scale to evaluate overall disease severity in patients with epidermolysis Bullosa simplex. J Invest Dermatol. 2017;137:S196.","journal-title":"J Invest Dermatol"},{"key":"3822_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.36849\/JDD.7108","volume":"22","author":"J Teng","year":"2023","unstructured":"Teng J, Paller AS, Bruckner AL, Murrell DF, Mellerio JE, Bodemer C, et al. Diacerein 1% ointment for the treatment of epidermolysis Bullosa simplex: A randomized, controlled trial. J Drugs Dermatol. 2023;22:599\u2013604.","journal-title":"J Drugs Dermatol"},{"key":"3822_CR39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2133.1991.tb04952.x","volume":"124","author":"B Ramsay","year":"1991","unstructured":"Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol. 1991;124:565\u201370.","journal-title":"Br J Dermatol"},{"key":"3822_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1034\/j.1600-0846.2003.00042.x","volume":"9","author":"YM Yune","year":"2003","unstructured":"Yune YM, Park SY, Oh HS, Kim DJ, Yoo DS, Kim IH, et al. Objective assessment of involved surface area in patients with psoriasis. Skin Res Technol. 2003;9:339\u201342.","journal-title":"Skin Res Technol"},{"issue":"Suppl 2","key":"3822_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1468-3083.2009.03562.x","volume":"24","author":"E Puzenat","year":"2010","unstructured":"Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):10\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3822_CR42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1089\/wound.2019.0967","volume":"9","author":"S Li","year":"2020","unstructured":"Li S, Mohamedi AH, Senkowsky J, Nair A, Tang L. Imaging in chronic wound diagnostics. Adv Wound Care (New Rochelle). 2020;9:245\u201363.","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"3822_CR43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13023-020-01443-3","volume":"15","author":"C Prodinger","year":"2020","unstructured":"Prodinger C, Diem A, Ude-Schoder K, Pinon-Hofbauer J, Kitzmueller S, Bauer JW, Laimer M. Profiling trial burden and patients\u2019 attitudes to improve clinical research in epidermolysis Bullosa. Orphanet J Rare Dis. 2020;15:182.","journal-title":"Orphanet J Rare Dis"},{"key":"3822_CR44","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1365-2133.2009.09041.x","volume":"160","author":"C Moss","year":"2009","unstructured":"Moss C, Wong A, Davies P. The Birmingham epidermolysis Bullosa severity score: development and validation. Br J Dermatol. 2009;160:1057\u201365.","journal-title":"Br J Dermatol"},{"key":"3822_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2013.09.041","volume":"70","author":"CC Loh","year":"2014","unstructured":"Loh CC, Kim J, Su JC, Daniel BS, Venugopal SS, Rhodes LM, et al. Development, reliability, and validity of a novel epidermolysis Bullosa disease activity and scarring index (EBDASI). J Am Acad Dermatol. 2014;70:89\u201397.","journal-title":"J Am Acad Dermatol"},{"key":"3822_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/pde.12317","volume":"32","author":"A Schwieger-Briel","year":"2015","unstructured":"Schwieger-Briel A, Chakkittakandiyil A, Lara-Corrales I, Aujla N, Lane AT, Lucky AW, et al. Instrument for scoring clinical outcome of research for epidermolysis Bullosa: a consensus-generated clinical research tool. Pediatr Dermatol. 2015;32:41\u201352.","journal-title":"Pediatr Dermatol"},{"key":"3822_CR47","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/bjd.16350","volume":"178","author":"AL Bruckner","year":"2018","unstructured":"Bruckner AL, Fairclough DL, Feinstein JA, Lara-Corrales I, Lucky AW, Tolar J, Pope E. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis Bullosa (iscorEB). Br J Dermatol. 2018;178:1128\u201334.","journal-title":"Br J Dermatol"},{"key":"3822_CR48","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/bjd\/ljad361","volume":"190","author":"EWH Korte","year":"2024","unstructured":"Korte EWH, Spuls PI, van den Akker PC, Kiritsi D, Laimer M, Pasmooij AMG, et al. Harmonization of outcomes in epidermolysis Bullosa: report of the core outcome sets for epidermolysis Bullosa (COSEB) kick-off meeting. Br J Dermatol. 2024;190:268\u201370.","journal-title":"Br J Dermatol"},{"key":"3822_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13023-016-0464-5","volume":"11","author":"RD Hilgers","year":"2016","unstructured":"Hilgers RD, Roes K, Stallard N, IdeAl A. Spg. Directions for new developments on statistical design and analysis of small population group trials. Orphanet J Rare Dis. 2016;11:78.","journal-title":"Orphanet J Rare Dis"},{"key":"3822_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1750-1172-3-11","volume":"3","author":"SC Chow","year":"2008","unstructured":"Chow SC, Chang M. Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis. 2008;3:11.","journal-title":"Orphanet J Rare Dis"},{"key":"3822_CR51","doi-asserted-by":"publisher","first-page":"s43586","DOI":"10.1038\/s43586-022-00100-2","volume":"2","author":"C Pizzamiglio","year":"2022","unstructured":"Pizzamiglio C, Vernon HJ, Hanna MG, Pitceathly RDS. Designing clinical trials for rare diseases: unique challenges and opportunities. Nat Rev Methods Primers. 2022;2:s43586\u2013022.","journal-title":"Nat Rev Methods Primers"},{"key":"3822_CR52","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s13023-023-02990-1","volume":"18","author":"M Geroldinger","year":"2023","unstructured":"Geroldinger M, Verbeeck J, Hooker AC, Thiel KE, Molenberghs G, Nyberg J, et al. Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials. Orphanet J Rare Dis. 2023;18:391.","journal-title":"Orphanet J Rare Dis"},{"key":"3822_CR53","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1111\/biom.13920","volume":"79","author":"J Verbeeck","year":"2023","unstructured":"Verbeeck J, Geroldinger M, Thiel K, Hooker AC, Ueckert S, Karlsson M, et al. How to analyze continuous and discrete repeated measures in small-sample cross-over trials? Biometrics. 2023;79:3998\u20134011.","journal-title":"Biometrics"},{"key":"3822_CR54","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13023-020-01419-3","volume":"15","author":"AS Paller","year":"2020","unstructured":"Paller AS, Browning J, Nikolic M, Bodemer C, Murrell DF, Lenon W, et al. Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis Bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). Orphanet J Rare Dis. 2020;15:158.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03822-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03822-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03822-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T06:02:31Z","timestamp":1750399351000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03822-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3822"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03822-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Photos of patients suffering from EBS were taken upon informed consent. Ethical approval was granted by the ethics committee of the county of Salzburg (vote number: 415-EP\/73\/192\u20132013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients gave written consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"V.W. and J.W.B. act as consultants for Diaderm GmbH and TWi Biotechnology and holds shares of Diaderm GmbH, a company with an interest in drug development for EB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"313"}}